Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 10, 2011, Pages 2048-2067

  Bhatia, Smita ^a  

^a City of Hope ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

BONE NECROSIS; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOMYOPATHY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MORBIDITY; NEOPLASM; OBESITY; OTOTOXICITY; OUTCOMES RESEARCH; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SECOND CANCER;

COMORBIDITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; PROGNOSIS; SURVIVAL RATE; SURVIVORS;

EID: 80053498348     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0659     Document Type: Review

References (175)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 60:277-300.
2. OCS: Office of Cancer Survivorship. National Cancer Institute; 2011.
3. Hewitt M, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academies Press; 2006.
4. Bhatia S, Robison LL. Cancer survivorship research: opportunities and future needs for expanding the research base. Cancer Epidemiol Biomarkers Prev 2008;17:1551-7.
5. Ganz PA. Why and how to study the fate of cancer survivors: observations from the clinic and the research laboratory. Eur J Cancer 2003;39:2136-41. (Pubitemid 37297737)
6. Oeffinger KC, Robison LL. Childhood cancer survivors, late effects, and a new model for understanding survivorship. JAMA 2007;297: 2762-4. (Pubitemid 47001104)
7. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008;94:525-33. (Pubitemid 351441417)
8. Kremer LC, Van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 2002;13:503-12. (Pubitemid 34461132)
9. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998;27:53-68. (Pubitemid 28275509)
10. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.
11. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84. (Pubitemid 30207690)
12. Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007;25:3635-43. (Pubitemid 47372601)
13. Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008;121:e387-96. (Pubitemid 351198462)
14. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 2005;44:600-6. (Pubitemid 40629208)
15. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56: 185-229. (Pubitemid 38720829)
16. Dell'Acqua G, Polishchuck R, Fallon JT, Gordon JW. Cardiac resistance to adriamycin in transgenicmice expressing a rat alpha-cardiac myosin heavy chain/human multiple drug resistance 1 fusion gene. Hum Gene Ther 1999;10:1269-79. (Pubitemid 29267582)
17. Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, Reeves RH. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 2003;63:6602-6. (Pubitemid 37336434)
18. Forrest GL, Gonzalez B, Tseng W, Li X, Mann J. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 2000;60:5158-64.
19. Van Dalen EC, Van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 2006;42:3191-8. (Pubitemid 44872945)
20. Paulides M, Kremers A, Stohr W, Bielack S, Jurgens H, Treuner J, et al. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer 2006;46:489-95. (Pubitemid 43334657)
21. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7:560-71. (Pubitemid 19126791)
22. Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 2007;7:129-34. (Pubitemid 47339859)
23. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxido-reductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008;112:2789-95. (Pubitemid 351969225)
24. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-62. (Pubitemid 43739516)
25. Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992;326:1473-9.
26. Ohzono K, Saito M, Takaoka K, Ono K, Saito S, Nishina T, et al. Natural history of nontraumatic avascular necrosis of the femoral head. J Bone Joint Surg Br 1991;73:68-72.
27. Heimann WG, Freiberger RH. Avascular necrosis of the femoral and humeral heads after high-dosage corticosteroid therapy. N Engl J Med 1960;263:672-5.
28. Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 2000;18: 3262-72.
29. Kadan-Lottick NS, Dinu I, Wasilewski-Masker K, Kaste S, Meacham LR, Mahajan A, et al. Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2008;26:3038-45.
30. Mattano LA Jr, Nachman JB, Devidas M, Winick N, Raetz E, Carroll WL, et al. Increased incidence of osteonecrosis (ON) with a dexamethasone (DEX) induction for high risk acute lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group (COG) [Abstract]. Blood 2008;112:333-4.
31. Teuffel O, Kuster SP, Hunger SP, Conter V, Hitzler J, Ethier MC, et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia 2011;25:1232-8.
32. Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004;22:3930-6. (Pubitemid 41079875)
33. Patel B, Richards SM, Rowe JM, Goldstone AH, Fielding AK. High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis. Leukemia 2008;22: 308-12. (Pubitemid 351250536)
34. Ribeiro RC, Fletcher BD, Kennedy W, Harrison PL, Neel MD, Kaste SC, et al. Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma. Leukemia 2001;15:891-7. (Pubitemid 32529887)
35. Arico M, Boccalatte MF, Silvestri D, Barisone E, Messina C, Chiesa R, et al. Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica 2003;88:747-53. (Pubitemid 36890108)
36. Hanada T, Horigome Y, Inudoh M, Takita H. Osteonecrosis of vertebrae in a child with acute lymphocytic leukaemia during L-asparaginase therapy. Eur J Pediatr 1989;149:162-3. (Pubitemid 20015178)
37. Sala A, Mattano LA Jr, Barr RD. Osteonecrosis in children and adolescents with cancer - an adverse effect of systemic therapy. Eur J Cancer 2007;43:683-9. (Pubitemid 46502899)
38. Harper PG, Trask C, Souhami RL. Avascular necrosis of bone caused by combination chemotherapy without corticosteroids. Br Med J (Clin Res Ed) 1984;288:267-8. (Pubitemid 14085692)
39. Marymont JV, Kaufman EE. Osteonecrosis of bone associated with combination chemotherapy without corticosteroids. Clin Orthop Relat Res 1986:150-3. (Pubitemid 16069370)
40. Ishii E, Yoshida N, Miyazaki S. Avascular necrosis of bone in neuroblastoma treated with combination chemotherapy. Eur J Pediatr 1984;143:152-3. (Pubitemid 15222538)
41. Abhyankar D, Nair R, Menon H, Kapoor B, Advani S. Avascular necrosis of head of femur in a patient with acute promyelocytic leukemia. Leuk Lymphoma 2000;37:635-7. (Pubitemid 30219075)
42. Smith RW, Margulis RR, Brennan MJ, Monto RW. The influence of ACTH and cortisone on certain factors of blood coagulation. Science 1950;112:295-7.
43. Yamamoto T, Hirano K, Tsutsui H, Sugioka Y, Sueishi K. Corticosteroid enhances the experimental induction of osteonecrosis in rabbits with Shwartzman reaction. Clin Orthop Relat Res 1995: 235-43.
44. Glueck CJ, Freiberg RA, Fontaine RN, Tracy T, Wang P. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res 2001: 19-33. (Pubitemid 32391273)
45. Yamamoto T, Irisa T, Sugioka Y, Sueishi K. Effects of pulse methylprednisolone on bone and marrow tissues: corticosteroid- induced osteonecrosis in rabbits. Arthritis Rheum 1997;40: 2055-64. (Pubitemid 27494667)
46. Yun SI, Yoon HY, Jeong SY, Chung YS. Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. J Bone Miner Metab 2009;27:140-8.
47. French D, Hamilton LH, Mattano LA Jr, Sather HN, Devidas M, Nachman JB, et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008;111:4496-9.
48. Asano T, Takahashi KA, Fujioka M, Inoue S, Satomi Y, Nishino H, et al. Genetic analysis of steroid-induced osteonecrosis of the femoral head. J Orthop Sci 2003;8:329-33. (Pubitemid 36702081)
49. Hadjigeorgiou G, Dardiotis E, Dardioti M, Karantanas A, Dimitroulias A, Malizos K. Genetic association studies in osteonecrosis of the femoral head: mini review of the literature. Skeletal Radiol 2008;37: 1-7. (Pubitemid 350160505)
50. Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011;117:2340-7; quiz 556.
51. Bottini N, MacMurray J, Peters W, Rostamkhani M, Comings DE. Association of the acid phosphatase (ACP1) gene with triglyceride levels in obese women. Mol Genet Metab 2002;77:226-9. (Pubitemid 35333827)
52. Zambuzzi WF, Granjeiro JM, Parikh K, Yuvaraj S, PeppelenboschMP, Ferreira CV. Modulation of Src activity by low molecular weight protein tyrosine phosphatase during osteoblast differentiation. Cell Physiol Biochem 2008;22:497-506.
53. Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 1989;7:754-60. (Pubitemid 19145597)
54. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004; 40:2445-51. (Pubitemid 39424959)
55. Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol 2007;29:355-60. (Pubitemid 46884215)
56. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005;23:8588-96. (Pubitemid 46211500)
57. Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006;107:417-22. (Pubitemid 44036572)
58. Blakley BW, Gupta AK, Myers SF, Schwan S. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 1994;120:541-6. (Pubitemid 24142680)
59. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14:2923-32. (Pubitemid 26371450)
60. Fossa SD. Long-term sequelae after cancer therapy - survivorship after treatment for testicular cancer. Acta Oncol 2004;43:134-41. (Pubitemid 38478899)
61. Hua C, Bass JK, Khan R, Kun LE, Merchant TE. Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys 2008;72:892-9.
62. Low WK, Toh ST, Wee J, Fook-Chong SM, Wang DY. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 2006;24:1904-9. (Pubitemid 46638990)
63. Merchant TE, Hua CH, Shukla H, Ying X, Nill S, Oelfke U. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer 2008;51:110-7. (Pubitemid 351717400)
64. Van Ruijven MW, De Groot JC, Smoorenburg GF. Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration. A quantitative histological study. Hear Res 2004;197: 44-54. (Pubitemid 39410692)
65. Roland JT, Cohen NL. Vestibular and auditory toxicity. In:Cummings CW, Fredrickson JM, Harker LA, et al., editors. Otolaryngology head and neck surgery. 3rd ed. St. Louis, MO: Mosby; 1998. p. 3186-97.
66. Paulino AC, Simon JH, Zhen W, Wen BC. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2000;48:1489-95.
67. Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007;25:708-14. (Pubitemid 350002927)
68. Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000;11:639-43.
69. Riedemann L, Lanvers C, Deuster D, Peters U, Boos J, Jurgens H, et al. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 2008;8: 23-8.
70. Ross CJ, Katzov-Eckert H, Dube MP, Brooks B, Rassekh SR, Barhdadi A, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009;41:1345-9.
71. Ochoa B, Bobadilla N, Arrellin G, Herrera LA. S-Adenosyl-L-methionine increases serum BUN and creatinine in cisplatin-treated mice. Arch Med Res 2009;40:54-8.
72. Dalton VK, Rue M, Silverman LB, Gelber RD, Asselin BL, Barr RD, et al. Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol 2003;21: 2953-60. (Pubitemid 46621847)
73. Oeffinger KC, Mertens AC, Sklar CA, Yasui Y, Fears T, Stovall M, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003;21:1359-65. (Pubitemid 46606416)
74. Razzouk BI, Rose SR, Hongeng S, Wallace D, Smeltzer MP, Zacher M, et al. Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. J Clin Oncol 2007;25:1183-9. (Pubitemid 46646518)
75. Garmey EG, Liu Q, Sklar CA, Meacham LR, Mertens AC, Stovall MA, et al. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2008;26: 4639-45.
76. Brennan BM, Rahim A, Blum WF, Adams JA, Eden OB, Shalet SM. Hyperleptinaemia in young adults following cranial irradiation in childhood: growth hormone deficiency or leptin insensitivity? Clin Endocrinol (Oxf) 1999;50:163-9. (Pubitemid 29100001)
77. Strosberg AD, Issad T. The involvement of leptin in humans revealed by mutations in leptin and leptin receptor genes. Trends Pharmacol Sci 1999;20:227-30. (Pubitemid 29295171)
78. Young EH, Wareham NJ, Farooqi S, Hinney A, Hebebrand J, Scherag A, et al. The V103I polymorphism of the MC4R gene and obesity: population based studies and meta-analysis of 29 563 individuals. Int J Obes (Lond) 2007;31:1437-41. (Pubitemid 47339918)
79. Geller F, Reichwald K, Dempfle A, Illig T, Vollmert C, Herpertz S, et al. Melanocortin-4 receptor gene variant I103 is negatively associated with obesity. Am J Hum Genet 2004;74:572-81. (Pubitemid 38325928)
80. Heid IM, Vollmert C, Hinney A, Doring A, Geller F, Lowel H, et al. Association of the 103I MC4R allele with decreased body mass in 7937 participants of two population based surveys. J Med Genet 2005;42:e21.
81. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007;316:889-94. (Pubitemid 46764279)
82. Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet 2007;39:724-6. (Pubitemid 46848595)
83. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 42: 937-48.
84. Ross JA, Oeffinger KC, Davies SM, Mertens AC, Langer EK, Kiffmeyer WR, et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2004;22: 3558-62. (Pubitemid 41103662)
85. Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010;102:1083-95.
86. Reulen RC, Frobisher C, Winter DL, Kelly J, Lancashire ER, Stiller CA, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA 2011;305:2311-9.
87. Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005;105:4215-22. (Pubitemid 40720765)
88. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008;100:1368-79.
89. Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati- Bellani F, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-51. (Pubitemid 26089355)
90. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ,Hammond S, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006;98:1528-37. (Pubitemid 44680904)
91. Neglia JP, Meadows AT, Robison LL, Kim TH, Newton WA, Ruymann FB, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991;325:1330-6.
92. Bhatia S, Krailo MD, Chen Z, Burden L, Askin FB, Dickman PS, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group. Blood 2007; 109:46-51. (Pubitemid 46053041)
93. Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, et al. High risk of subsequent neoplasms continues with extended followup of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003;21:4386-94. (Pubitemid 46621816)
94. Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer 2002;2:124-32. (Pubitemid 37328799)
95. Bhatia S, Sather HN, Pabustan OB, Trigg ME, Gaynon PS, Robison LL. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002;99: 4257-64. (Pubitemid 34627190)
96. Travis LB, Andersson M, Gospodarowicz M, Van Leeuwen FE, Bergfeldt K, Lynch CF, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000;92:1165-71.
97. Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wiklund T, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340:351-7. (Pubitemid 29090800)
98. Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000;95:1588-93. (Pubitemid 30120817)
99. Howe R, Micallef IN, Inwards DJ, Ansell SM, Dewald GW, Dispenzieri A, et al. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2003;32:317-24. (Pubitemid 36927085)
100. Laughlin MJ, McGaughey DS, Crews JR, Chao NJ, Rizzieri D, Ross M, et al. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol 1998;16:1008-12. (Pubitemid 28108734)
101. Stone RM. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress. Blood 1994;83: 3437-40. (Pubitemid 24175529)
102. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996;95: 349-53. (Pubitemid 26360224)
103. Bhatia S, Ramsay NKC, Steinbuch M, Dusenbury KE, Shapiro RS, Weisdorf DJ, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633-9. (Pubitemid 26129591)
104. Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 2005;365:2014-23. (Pubitemid 40805009)
105. Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001;93:618-29. (Pubitemid 32409629)
106. Boice JD Jr, Land C, Preston DL. Ionizing radiation. In:Schottenfield D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention.New York: Oxford University Press; 1996. p. 319-54.
107. Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 1994;137: S68-97. (Pubitemid 24060247)
108. Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S, et al. Cancer incidence in atomic bomb survivors. Part II: solid tumors, 1958-1987. Radiat Res 1994;137:S17-67. (Pubitemid 24060246)
109. Ron E, Modan B, Preston D, Alfandary E, Stovall M, Boice JD Jr. Radiation-induced skin carcinomas of the head and neck. Radiat Res 1991;125:318-25.
110. Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997;278:1262-7. (Pubitemid 27435614)
111. Strong LC, Stine M, Norsted TL. Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 1987;79:1213-20. (Pubitemid 18036724)
112. Land CE, Saku T, Hayashi Y, Takahara O, Matsuura H, Tokuoka S, et al. Incidence of salivary gland tumors among atomic bomb survivors, 1950-1987. Evaluation of radiation-related risk. Radiat Res 1996;146:28-36. (Pubitemid 26230830)
113. Kenney LB, Yasui Y, Inskip PD, Hammond S, Neglia JP, Mertens AC, et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med 2004;141: 590-7. (Pubitemid 39390536)
114. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004;18:120-5. (Pubitemid 38159447)
115. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43-52. (Pubitemid 36759634)
116. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006;20:1943-9. (Pubitemid 44614882)
117. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100:2292-302.
118. Van Leeuwen FE, Travis LB. Second cancers. In:DeVita HS, Rosenberg SA, editors. Cancer: principles and practice of oncology 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005. p. 2575-602.
119. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985;65:1364-72. (Pubitemid 15057942)
120. Travis LB, Hill D, Dores GM, Gospodarowicz M, Van Leeuwen FE, Holowaty E, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97:1428-37. (Pubitemid 41520078)
121. Henderson TO, Whitton J, Stovall M, Mertens AC, Mitby P, Friedman D, et al. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2007;99:300-8. (Pubitemid 47073493)
122. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001;96:238-42. (Pubitemid 33081228)
123. Alter BP. Cancer in Fanconi anemia,1927-2001. Cancer 2003;97: 425-40.
124. Tischkowitz M, Dokal I. Fanconi anaemia and leukaemia - clinical and molecular aspects. Br J Haematol 2004;126:176-91. (Pubitemid 38961936)
125. Rosenberg PS, Alter BP, Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica 2008;93:511-7. (Pubitemid 351536378)
126. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005;19:2925-40. (Pubitemid 41798109)
127. Kalow W, Ozdemir V, Tang BK, Tothfalusi L, Endrenyi L. The science of pharmacological variability: an essay. Clin Pharmacol Ther 1999; 66:445-7.
128. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49. (Pubitemid 36159890)
129. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000;92:874-97. (Pubitemid 30429188)
130. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-30. (Pubitemid 36020002)
131. Bhatti P, Doody MM, Alexander BH, Yuenger J, Simon SL, Weinstock RM, et al. Breast cancer risk polymorphisms and interaction with ionizing radiation among U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev 2008;17:2007-11.
132. Bhatti P, Struewing JP, Alexander BH, Hauptmann M, Bowen L, Mateus-Pereira LH, et al. Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists. Int J Cancer 2008;122:177-82. (Pubitemid 350209993)
133. Rajaraman P, Bhatti P, Doody MM, Simon SL, Weinstock RM, Linet MS, et al. Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists. Int J Cancer 2008;123:2713-6.
134. Worrillow LJ, Travis LB, Smith AG, Rollinson S, Smith AJ, Wild CP, et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 2003;9:3012-20. (Pubitemid 36993261)
135. Allan JM, Smith AG, Wheatley K, Hills RK, Travis LB, Hill DA, et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004;104:3872-7. (Pubitemid 39620132)
136. Mertens AC, Mitby PA, Radloff G, Jones IM, Perentesis J, Kiffmeyer WR, et al. XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. Cancer 2004;101:1463-72. (Pubitemid 39180403)
137. Worrillow LJ, Smith AG, Scott K, Andersson M, Ashcroft AJ, Dores GM, et al. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet 2008;45:142-6. (Pubitemid 351373742)
138. McFadyen MC, Melvin WT, Murray GI. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 2004;3: 363-71. (Pubitemid 39193712)
139. Park JY, Shigenaga MK, Ames BN. Induction of cytochrome P4501A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin or indolo(3,2-b)carbazole is associated with oxidative DNA damage. Proc Natl Acad Sci U S A 1996;93:2322-7. (Pubitemid 26104348)
140. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88. (Pubitemid 40261798)
141. Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A 2001;98:11592-7. (Pubitemid 32928773)
142. Rund D, Krichevsky S, Bar-Cohen S, Goldschmidt N, Kedmi M, Malik E, et al. Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia 2005;19:1919-28. (Pubitemid 41554000)
143. Collins A, Harrington V. Repair of oxidative DNA damage: assessing its contribution to cancer prevention. Mutagenesis 2002;17:489-93. (Pubitemid 35414777)
144. Karran P, Offman J, Bignami M. Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie 2003;85: 1149-60. (Pubitemid 38142368)
145. Casorelli I, Offman J, Mele L, Pagano L, Sica S, D'Errico M, et al. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst) 2003;2: 547-59. (Pubitemid 36507123)
146. Seedhouse CH, Das-Gupta EP, Russell NH. Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia 2003;17:83-8. (Pubitemid 36175892)
147. Zhu YM, Das-Gupta EP, Russell NH. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood 1999;94:733-40. (Pubitemid 29323887)
148. Horiike S, Misawa S, Kaneko H, Sasai Y, Kobayashi M, Fujii H, et al. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/ or 7 and its possible relationship to replication error phenotype. Leukemia 1999;13:1235-42. (Pubitemid 29396584)
149. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;75:1027-38. (Pubitemid 24014559)
150. Brentnall TA, Rubin CE, Crispin DA, Stevens A, Batchelor RH, Haggitt RC, et al. A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology 1995;109:151-5.
151. Worrillow LJ, Allan JM. Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia. Oncogene 2006;25:1709-20.
152. O'Driscoll M, Jeggo PA. The role of double-strand break repair - insights from human genetics. Nat Rev Genet 2006;7:45-54. (Pubitemid 41828947)
153. Baumann P, West SC. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 1998;23:247-51. (Pubitemid 28343368)
154. Jawad M, Seedhouse CH, Russell N, Plumb M. Polymorphisms in human homeobox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukemia. Blood 2006;108: 3916-8. (Pubitemid 44864577)
155. Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004;10:2675-80. (Pubitemid 38509141)
156. Bishop DK, Ear U, Bhattacharyya A, Calderone C, Beckett M, Weichselbaum RR, et al. Xrcc3 is required for assembly of Rad51 complexes in vivo. J Biol Chem 1998;273:21482-8. (Pubitemid 28405315)
157. Liu N, Lamerdin JE, Tebbs RS, Schild D, Tucker JD, Shen MR, et al. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol Cell 1998;1:783-93. (Pubitemid 128379063)
158. Tebbs RS, Zhao Y, Tucker JD, Scheerer JB, Siciliano MJ, Hwang M, et al. Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proc Natl Acad Sci U S A 1995;92:6354-8.
159. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999;13:2633-8. (Pubitemid 29508550)
160. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998;58:604-8. (Pubitemid 28099464)
161. Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)PDNA adducts in a sample of healthy subjects. Carcinogenesis 2001;22:1437-45. (Pubitemid 32898701)
162. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003;111:1843-50. (Pubitemid 37526965)
163. Coiteux V, Onclercq-Delic R, Fenaux P, Amor-Gueret M. Predisposition to therapy-related acute leukemia with balanced chromosomal translocations does not result from a major constitutive defect in DNA double-strand break end joining. Leuk Res 2007;31:353-8. (Pubitemid 46073172)
164. Caldecott KW, McKeown CK, Tucker JD, Ljungquist S, Thompson LH. An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. Mol Cell Biol 1994;14:68-76.
165. Kubota Y, Nash RA, Klungland A, Schar P, Barnes DE, Lindahl T. Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J 1996;15:6662-70. (Pubitemid 26413798)
166. Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 2002;100:3761-6. (Pubitemid 35303949)
167. Nelson HH, Kelsey KT, Mott LA, Karagas MR. The XRCC1 Arg399Gln polymorphism, sunburn, and non-melanoma skin cancer: evidence of gene-environment interaction. Cancer Res 2002;62:152-5. (Pubitemid 34073999)
168. Wu X, Gu J, Amos CI, Jiang H, Hong WK, Spitz MR. A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls. Cancer 1998;83:1118-27. (Pubitemid 28419064)
169. Vijayalaxmi,Leal BZ, Deahl TS, Meltz ML. Variability in adaptive response to low dose radiation in human blood lymphocytes: consistent results from chromosome aberrations and micronuclei. Mutat Res 1995;348:45-50.
170. Godderis L, Aka P, Mateuca R, Kirsch-Volders M, Lison D, Veulemans H. Dose-dependent influence of genetic polymorphisms on DNA damage induced by styrene oxide, ethylene oxide and gamma-radiation. Toxicology 2006;219:220-9. (Pubitemid 43120722)
171. Marcon F, Andreoli C, Rossi S, Verdina A, Galati R, Crebelli R. Assessment of individual sensitivity to ionizing radiation and DNA repair efficiency in a healthy population. Mutat Res 2003; 541:1-8. (Pubitemid 38368653)
172. Collins FS, Brooks LD, Chakravarti A. A DNA polymorphism discovery resource for research on human genetic variation. Genome Res 1998;8:1229-31. (Pubitemid 29039095)
173. Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008;112: 741-9.
174. Knight JA, Skol AD, Shinde A, Hastings D, Walgren RA, Shao J, et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood 2009;113: 5575-82.
175. Best T, Li D, Skol AD, Kirchhoff T, Jackson SA, Yasui Y, et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 2011;17:941-3.